Biotech Values

[genisi]

How do we know daclatasvir isn't the issue

In addition to what jq1234 pointed out (on the more extensive clinical data available for daclatasvir), there may also have been signs for the very same tox observed in the phase II trial, in the preclinical data of the nuke but not the NS5A. That would strongly suggest which drug is the issue.